Several therapies are available for treatment of second- and subsequent-line advanced/ metastatic colorectal cancer that have a positive effect of patient survival, but none of them are able to cure the disease. Furthermore, some therapies used are associated with side effects that can significantly decrease patients’ quality of life and can also prevent patients from receiving treatment. Hence, there is an unmet need for novel efficacious therapies with an improved safety and tolerability profile, and this Unmet Need module examines the key drivers of prescribing in this indication and analyses significant commercial opportunities. 

Table of contents

  • Detailed, Expanded Analysis: Second- and Subsequent-Lines Advanced/Metastatic Colorectal Cancer
    • Treatment Drivers and Goals
      • Overview
      • Treatment Drivers and Goals
        • Methodology
        • Physician Weighting of Clinical and Non-Clinical Attributes
        • Rationale for Treatment Drivers and Goals Selection
      • Physician Rating of Treatment Drivers and Goals in Second- and Subsequent-Line Colorectal Cancer
        • Efficacy
        • Safety and Tolerability
        • Non-Clinical Factors
      • Stated Versus Derived Importance of Treatment Drivers and Goals
      • Abbreviations
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Efficacy
        • Safety and Tolerability
        • Non-Clinical Factors
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
      • Physician Rating of Unmet Need in Second- and Subsequent-Lines Advanced/Metastatic Colorectal Cancer
        • Efficacy
        • Safety and Tolerability
        • Non-Clinical Factors
      • Unmet Need in Second- and Subsequent-Lines Advanced/Metastatic Colorectal Cancer and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Second- and Subsequent-Lines Advanced/Metastatic Colorectal Cancer Market and Emerging Therapy Insight
        • Opportunity: A Novel Therapy That Can Significantly Increase OS
        • Opportunity: A Novel Therapy That Improves PFS and/or ORR
        • Opportunity: A Therapy with an Improved Safety and Tolerability Profile
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2

Author(s): Karen Pomeranz, PhD; Steven Tinsley, PhD, MSc

Karen Pomeranz is a senior business insights analyst analyst in the oncology team at Decision Resources Group. She has worked on a breadth of indications including glioma, hepatocellular carcinoma, gastrointestinal stromal tumor, malignant melanoma, renal cell carcinoma, breast cancer, and colorectal cancer. She has worked on several products lines as well as with the Decision Resources Group consulting team on many projects. Her previous work experience includes conducting scientific research at Imperial College, London and Tel-Aviv University. Dr. Pomeranz holds an from Tel-Aviv University and a from Imperial College, London.

Steven Tinsley, , is a business insights analyst with the oncology division at Decision Resources Group. Dr. Tinsley obtained his doctorate in acute myeloid leukemia (AML) from University College London, where he focused on establishing the role of mutations in c-KIT in the pathogenesis and therapy of core-binding factor-related AML, and received his in stem cell technology and his in human genetics from the University of Nottingham. Prior to joining DRG, Dr. Tinsley was a grants adviser at the Wellcome Trust.


Related Reports

Colorectal Cancer | Geographic Focus - China | Colorectal Cancer - China In-Depth - China

MARKET OUTLOOK Colorectal cancer, a major public health concern in China, is expected to become the second most common form of cancer there by 2028, behind only lung can...

View Details

Colorectal Cancer | Landscape & Forecast | Disease Landscape & Forecast

Colorectal cancer is the third-most-common cancer globally, and metastatic disease is associated with poor five-year overall survival rates. Current treatment for metastatic colorectal cancer is...

View Details

Colorectal Cancer | Epidemiology | Emerging Markets

DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide....

View Details

Colorectal Cancer | Current Treatment | Detailed, Expanded Analysis (US)

Market Outlook Chemotherapies and targeted agents continue to dominate the treatment of colorectal cancer, although targeted agents (e.g., Avastin, Erbitux, Vectibix) ar...

View Details